IFP Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-13,509
| Closed | -$3.33K | – | 5267 |
|
|
2026
Q1 | $3.33K | Buy |
+13,509
| New | +$5.38K | ﹤0.01% | 3758 |
|
|
2023
Q1 | – | Sell |
-3,688
| Closed | -$62K | – | 4268 |
|
|
2022
Q4 | $62K | Sell |
3,688
-410
| -10% | -$1.59K | ﹤0.01% | 2090 |
|
|
2022
Q3 | $70K | Hold |
4,098
| – | – | ﹤0.01% | 2122 |
|
|
2022
Q2 | $70K | Hold |
4,098
| – | – | ﹤0.01% | 1926 |
|
|
2022
Q1 | $70K | Buy |
+4,098
| New | +$24.4K | ﹤0.01% | 1926 |
|
|
2021
Q3 | – | Sell |
-206
| Closed | -$3K | – | 3446 |
|
|
2021
Q2 | $3K | Sell |
206
-44
| -18% | -$498 | ﹤0.01% | 2660 |
|
|
2021
Q1 | $3K | Sell |
250
-19
| -7% | -$256 | ﹤0.01% | 2587 |
|
|
2020
Q4 | $4K | Buy |
269
+65
| +32% | +$761 | ﹤0.01% | 2428 |
|
|
2020
Q3 | $1K | Buy |
204
+48
| +31% | +$519 | ﹤0.01% | 2707 |
|
|
2020
Q2 | $1K | Hold |
156
| – | – | ﹤0.01% | 2604 |
|
|
2020
Q1 | $1K | Hold |
156
| – | – | ﹤0.01% | 2605 |
|
|
2019
Q4 | $1K | Sell |
156
-3
| -2% | -$28 | ﹤0.01% | 2719 |
|
|
2019
Q3 | $1K | Buy |
+159
| New | +$1.78K | ﹤0.01% | 2925 |
|
|
2018
Q4 | – | Sell |
-500
| Closed | -$8K | – | 3827 |
|
|
2018
Q3 | $8K | Buy |
500
+380
| +317% | +$5.78K | ﹤0.01% | 2990 |
|
|
2018
Q2 | $2K | Buy |
120
+8
| +7% | +$133 | ﹤0.01% | 3629 |
|
|
2018
Q1 | $2K | Hold |
112
| – | – | ﹤0.01% | 3539 |
|
|
2017
Q4 | $2K | Buy |
112
+7
| +7% | +$104 | ﹤0.01% | 3590 |
|
|
2017
Q3 | $2K | Buy |
+105
| New | +$1.16K | ﹤0.01% | 3783 |
|
Other funds holding SGMO
IFP Advisors's SGMO Position: Q2 2026 in Review
IFP Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 13,509 shares — an estimated $3.33K sold.
IFP Advisors first reported a position in SGMO in Q3 2017 and held it in 18 quarters. The position peaked at $70K in Q3 2022. 2 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.
- IFP Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
- IFP Advisors sold 13,509 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $3.33K.
- IFP Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q3 2017 and held it in 18 quarters.
- IFP Advisors's SANGAMO THERAPEUTICS INC position peaked at $70K in Q3 2022.
- 2 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.
Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.